China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody (mAb) injection Xintituo (siltartoxatug) in Zhuhai, Guangdong province. This marks a significant advancement in the treatment and prevention of tetanus, offering a more efficient and safer alternative to traditional methods.
Advantages Over Traditional Products
Traditional horse serum products for tetanus prevention and treatment require patients to undergo skin testing and are prone to causing allergies. The desensitization treatment, which requires multiple injections and 30 minutes of observation per injection, is cumbersome and time-consuming. Moreover, treatment for severely injured patients is extremely time-sensitive. In contrast, Xintituo demonstrates rapid onset and a longer duration of protection. Preclinical data shows that 95.4% of patients reached a protective level within 12 hours of receiving siltartoxatug.
Market Implications
The introduction of Xintituo addresses the limitations of current tetanus vaccines, which typically take two days to reach their protective peak in the body. This innovative therapy has the potential to become a preferred choice for both prophylactic and therapeutic use in tetanus cases, significantly improving patient outcomes and reducing the risk of allergic reactions.-Fineline Info & Tech
Leave a Reply